SCCM is updating its SCCM Connect Community. Access to SCCM Connect may be limited until April 23.

Tag: Pharmacology

Tag Search

visual bubble
visual bubble
visual bubble
visual bubble

FDA Updates Sotrovimab Emergency Use Authorization

The Centers for Disease Control and Prevention (CDC) Nowcast data from April 5, 2022,  estimates that the proportion of COVID-19 cases caused by the Omicron BA.2 variant is above 50% in all Health and Human Services (HHS) U.S. regions. Data included in the health care provider fact sheet show the authorized dose of sotrovimab is unlikely to be effective against the BA.2 sub-variant. Due to these data, sotrovimab is not authorized in any U.S. state or territory at this time. 


New Paxlovid Dose Pack Author​ized by FDA

On April 14, 2022, the FDA revised the Emergency Use Authorization (EUA) for the COVID-19 oral antiviral therapeutic Paxlovid to authorize an additional dose pack presentation with appropriate dosing for patients with moderate renal impairment within the scope of the EUA. As a result, Paxlovid will soon be available in two package presentations. 


Tocilizumab May Reduce Mortality in Certain COVID-19 Patients

Two recent trials suggest that immune-damping drugs such as tocilizumab may reduce mortality in patients with severe COVID-19.


Concise Critical Appraisal: Antipsychotic Medications for Delirium in the ICU

Girard et al (N Engl J Med. 2018;379:2506-2516) and Page et al (Lancet Respir Med. 2013;1:515-523) evaluated the treatment of acute delirium with antipsychotics.